Is MEDNAX, Inc. (NYSE:MD) Overpaying Its CEO?

In 2003 Roger Medel was appointed CEO of MEDNAX, Inc. (NYSE:MD). First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap shot of the business growth. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO.

View our latest analysis for MEDNAX

How Does Roger Medel’s Compensation Compare With Similar Sized Companies?

At the time of writing our data says that MEDNAX, Inc. has a market cap of US$2.0b, and is paying total annual CEO compensation of US$9.9m. (This is based on the year to December 2018). While this analysis focuses on total compensation, it’s worth noting the salary is lower, valued at US$1.0m. We examined companies with market caps from US$1.0b to US$3.2b, and discovered that the median CEO total compensation of that group was US$4.0m.

It would therefore appear that MEDNAX, Inc. pays Roger Medel more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn’t mean the remuneration is too high. We can better assess whether the pay is overly generous by looking into the underlying business performance.

You can see, below, how CEO compensation at MEDNAX has changed over time.

NYSE:MD CEO Compensation, July 29th 2019
NYSE:MD CEO Compensation, July 29th 2019

Is MEDNAX, Inc. Growing?

Over the last three years MEDNAX, Inc. has shrunk its earnings per share by an average of 4.6% per year (measured with a line of best fit). In the last year, its revenue is up 4.9%.

Few shareholders would be pleased to read that earnings per share are lower over three years. The modest increase in revenue in the last year isn’t enough to make me overlook the disappointing change in earnings per share. It’s hard to argue the company is firing on all cylinders, so shareholders might be averse to high CEO remuneration.

Has MEDNAX, Inc. Been A Good Investment?

Given the total loss of 65% over three years, many shareholders in MEDNAX, Inc. are probably rather dissatisfied, to say the least. So shareholders would probably think the company shouldn’t be too generous with CEO compensation.

In Summary…

We compared total CEO remuneration at MEDNAX, Inc. with the amount paid at companies with a similar market capitalization. Our data suggests that it pays above the median CEO pay within that group.

Neither earnings per share nor revenue have been growing sufficiently fast to impress us, over the last three years.

Just as bad, share price gains for investors have failed to materialize, over the same period. This analysis suggests to us that the CEO is paid too generously! Shareholders may want to check for free if MEDNAX insiders are buying or selling shares.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.